摘要
目的探讨慢性淋巴细胞性白血病(CLL)患者外周血中调节性T细胞(Treg)表达及其与预后的相关性。方法采用流式细胞术检测30例健康体检者和28例初诊的CLL患者治疗前后外周血的CD4+CD25+Treg、CD4+CD25+Foxp3+Treg数量,并对19例患者进行了治疗随访。结果初诊CLL患者CD4+CD25+Treg高于健康对照组,差异有统计学意义(P<0.05);初诊CLL患者CD4+CD25+Foxp3+Treg分别高于治疗后组和健康对照组,差异均有统计学意义(P<0.05),治疗后CD4+CD25+Foxp3+Treg高于健康对照组,差异有统计学意义(P<0.05)。初诊CLL患者CD4+CD25+Foxp3+Treg与CD38表达率、β2微球蛋白表达量、Zeta相关蛋白70(ZAP-70)阳性表达、临床Binet分期和Rai分期均呈正相关。结论 CD4+CD25+Foxp3+Treg有可能作为评估CLL患者疾病进展、疗效及预后的指标之一。
Objective To explore the percentage of CD4＋ CD25 ＋ Foxp3 ＋ regulatory T cells （Treg） in peripheral blood ofchronic lymphocytic leukemia （CLL） patients and the correlations with clinical prognosis. Methods The study enrolled 30healthy individuals and 28 CLL patients. The CD4＋ CD25＋ Treg and CD4＋ CD25＋ Foxp3＋ Treg were detected by the flowcytometry in their peripheral blood. Of the 28 CLL patients, 19 received treatment and follow-up. Results The number ofCD4 ＋ CD25＋ Treg in the pre-treated cases （n = 28） was higher than that in the healthy controls （n = 30） with significantstatistical difference （P 〈0.05） . The number of CD4 ＋ CD25 ＋ Foxp3＋ Treg was higher in the pre-treated cases （n = 28） thanthat in the treated cases （n = 19） and in the healthy controls （n = 30） （P〈0.05）. Compared with the healthy controls, thetreated cases （n = 19） had the higher level of CD4 ＋ CD25 ＋ Foxp3 ＋ Treg （P〈0.05）. The CD4 ＋ CD25 ＋ Foxp3 ＋ Treg waspositively correlated with the expressions of CD38, p2-microglobulin （β2-MG）,zeta-associated protein 70（ZAP-70） and theclinical Binet and Rai stages. Conclusion The CD4＋ CD25＋ Foxp3＋ Treg might be a valuable indicator for assessing thetherapeutic efficacy, disease progression and prognosis of the CLL patients.
出处
《细胞与分子免疫学杂志》
CAS
CSCD
北大核心
2013年第12期1307-1311,共5页
Chinese Journal of Cellular and Molecular Immunology
基金
新疆维吾尔自治区自然科学基金(2013211A100)
